Hormonal contraceptive with anti mineral corticoid and
antiandrogene effect: efficacy and tolerance
Prilepskaya V.N., Ostreykova L.I .
Research Centre of Obstetrics, Gynecology and Perinatology,
Combined oral contraceptive Yarina (Yasmin) containing 0.03 mg
ethynilestradiol and 3 mg new gestagen drospirenon is a novel stage in hormonal
contraception. Drospirenon is a derivative of 17-alpha-spironolacton and in some
features is similar to it. Due to unique antimineralcorticoid and antiandrogene
effects the use of Yarina arrests eodema in an organism and thus improves the
tolerance of hormonal contraception.
Objectives: Analysis of efficacy and tolerance of oral
contraceptive Yarina in women of reproductive age.
Materials and methods: 68 women, aged 18 to 39 (mean age
24 +/- 3.2) without any contraindications to hormonal contraception. Follow-up
period was 12 months. All patients were examined with clinical methods and Pape
smear test. All women were requested to keep menstrual daybook.
Results: At initial examination 19 patients demonstrated
the symptoms of premenstrual syndrome. Subjective and objective status of
patients was assessed according to specially elaborated questionnaire. All
patients were noted to have the signs of irritation on days 4 – 10 prior to
menstrual onset, 4 had depressive status, headaches, oedema was noted in 15
cases. No patient was registered to conceive during contraception.
Intramenstrual bleedings were found in 2 women, vomiting in one. Decrease or
elimination of premenstrual symptoms were detected in 14 out of 15 patients.
Conclusion: Yarina is highly effective contraceptive. It
is generally well tolerated, achieving good cycle control and having beneficial
effects on acne and other skin-related conditions. There is evidence to suggest
that Yarina has a beneficial effect in the treatment of premenstrual syndrome as
well as having a positive effect on well-being and health-related quality of
life. Overall, Yarina is a promising treatment option for women requiring